ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC

Lung Cancer, Nonsmall Cell Clinical Trial

— CONTINUE  

Official title:

Consolidation Toripalimab Therapy Guided by Circulating Tumor DNA (ctDNA)-Minimal Residual Disease (MRD) for Completely Resected Stage IB-IIIA Non-small-cell Lung Cancer (Without EGFR or ALK Alterations for Nonsquamous Lung Cancer)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06426511
• Other study ID #: GASTO10112
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: July 1, 2024
• Est. completion date: July 1, 2029

Study information

• Verified date: May 2024
• Source: Sun Yat-sen University
• Contact: Si-Yu Wang, MD
• Phone: +86 20 87343439
• Email: wangsy[@]sysucc.org.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to incorporate circulating tumor DNA (ctDNA)-minimal residual disease (MRD) to personalize the administration of consolidation toripalimab therapy in resected stage IB-IIIA non-small-cell lung cancer (NSCLC) after adjuvant therapy. Toripalimab is a humanized monoclonal antibody for human programmed cell death protein 1. Toripalimab was approved as a consolidation treatment after perioperative therapy in combination with chemotherapy for resectable stage III NSCLC.

Description:

Most patients with stage IB-IIIA non-small cell lung cancer (NSCLC) are managed with surgery, follow by standard-of-care adjuvant platinum-based chemotherapy. However, postoperative recurrence rates remain high. Recent years, the role of checkpoint inhibitors has been proven to be effective in patients with advanced NSCLC, and even in patients with resectable NSCLC. Emerging data supports the use of consolidation checkpoint inhibitors therapy in localized NSCLC. Based on the results from Neotorch trial, consolidation toripalimab therapy led to a significant improvement in event-free survival for patients with resectable NSCLC. However, not all patients may benefit from consolidation therapy. Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for early detection of minimal residual disease (MRD) in cancer surveillance. There is a critical need to identify MRD after curative therapies to determine which patients may benefit from consolidation toripalimab therapy. The aim of this study is to explore whether observation follow-up for patients with negative ctDNA after adjuvant therapy has a non-inferior prognosis for patients with positive ctDNA and received consolidation toripalimab therapy. This study aims to incorporate ctDNA-MRD to personalize the administration of consolidation toripalimab therapy for completely resected stage IB-IIIA NSCLC (without EGFR or ALK alterations for nonsquamous NSCLC).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 80
• Est. completion date: July 1, 2029
• Est. primary completion date: July 1, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Subjects must have undergone complete surgical resection (R0) of their stage IB , II and select IIIA NSCLC according to the AJCC 8th edition staging;

• Squamous or non-squamous NSCLC histology;

• Subjects should be without EGFR or ALK alterations for nonsquamous NSCLC;

• Male and female, aged 18-75 years;

• Surgery for lung cancer must be completed = 60 days prior to study treatment;

• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;

• Adequate hematological function: Absolute neutrophil count (ANC) =2.0 x 109/L, and Platelet count =100 x 109/L, and Hemoglobin =9 g/dL (may be transfused to maintain or exceed this level);

• Adequate liver function: Total bilirubin = 1.5 x upper limit of normal (ULN), Aspartate aminotransferase (AST), alanine aminotransferase (ALT) = 2.5 x ULN;

• Adequate renal function: Serum creatinine = 1.25 x ULN, or = 60 ml/min;

• Female subjects should not be pregnant or breast-feeding;

• Written informed consent provided. Being willing and able to comply with the visits, treatment plan, laboratory examinations and other study procedures scheduled in the study.

Exclusion Criteria:

• Not R0 resection, or metastatic disease.

• Subjects with known EGFR sensitive mutations or ALK translocation, EGFR and ALK mutation status needs to be identified for the subjects with non-squamous NSCLC;

• Previous treatment with systemic antitumor therapy for NSCLC;

• Severe allergic reaction to other monoclonal antibodies;

• Subjects with any known or suspected autoimmune disorder or immunodeficiency, with the following exceptions: hypothyroidism, hormone therapy is not needed, or well controlled at physiological dose; controlled type I diabetes;

• Uncontrolled active hepatitis B (defined as positive hepatitis B surface antigen in screening period with HBV-DNA detected higher than the upper limit of normal at the clinical laboratory of the study center); active hepatitis C (defined as positive hepatitis C surface antibody in screening period and positive HCV-RNA);

• Vaccination of live vaccine within 30 days prior to the first dose;

• Evidence of clinically active interstitial lung disease;

• Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS);

• Inability to comply with protocol or study procedures;

• Any unstable systemic disease (including active infection, active tuberculosis uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease);

• A serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study and may confuse the study results;

• History of another malignancy in the last 5 years with the exception of the following:

other malignancies cured by surgery alone and having a continuous disease-free interval of 5 years are permitted. Cured basal cell carcinoma of the skin and cured in situ carcinoma of the uterine cervix are permitted.

• Women who are pregnant or nursing.

• Ingredients mixed with small cell lung cancer patients.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Cancer, Nonsmall Cell
• Lung Neoplasms

Intervention

Drug:
• Toripalimab+Chemotherapy
After surgical resection, patients received 4 cycle of toripalimab (240 mg) in combination with platinum-based adjuvant treatment. Administration of standard postoperative adjuvant chemotherapy for stage IB disease was not mandatory; decisions about whether patients with IB disease would receive adjuvant chemotherapy were made by the physicians.
• Toripalimab+Chemotherapy followed by consolidation toripalimab
After surgical resection, patients received 4 cycle of toripalimab (240 mg) in combination with platinum-based adjuvant treatment, and then maintenance treatment with single-agent toripalimab (240 mg) once every 3 weeks for up to 13 cycles. Administration of standard postoperative adjuvant chemotherapy for stage IB disease was not mandatory; decisions about whether patients with IB disease would receive adjuvant chemotherapy were made by the physicians.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Sun Yat-sen University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The 2-year DFS rate of ctDNA-MRD guided consolidation toripalimab	Determine if ctDNA-MRD guided consolidation toripalimab has a non-inferior 2-year DFS to direct 13 cycles of consolidation toripalimab therapy.; 2-year DFS was defined as the proportion of patients who were disease free at 2 years.	Baseline to 24 months
Secondary	The 2-year OS rate of ctDNA-MRD guided consolidation toripalimab	Determine if ctDNA-MRD guided consolidation toripalimab has a non-inferior 2-year OS to direct 13 cycles of consolidation toripalimab therapy.; 2-year OS was defined as the proportion of patients who were alive at 2 years.	Baseline to 24 months
Secondary	The 2-year DFS in patients with persistently detectable ctDNA	Estimate the 2-year DFS in patients with persistently detectable ctDNA after receiving =6 months of consolidation toripalimab.	Baseline to 24 months
Secondary	Percentage of patients with undetectable ctDNA after consolidation toripalimab.	Percentage of patients with undetectable ctDNA after consolidation toripalimab of 13 cycles.	Baseline to 15 months
Secondary	Percentage of patients with detectable ctDNA after adjuvant chemotherapy plus toripalimab.	Percentage of patients with detectable ctDNA after 4 cycles of adjuvant chemotherapy plus toripalimab.	Baseline to 3 months
Secondary	Adverse Events	Adverse Events were monitored according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.	Baseline to 36 months